Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 257Carcinoma, Intraductal, Noninfiltrating 24Breast Carcinoma In Situ 21Neoplasms 12Neoplasm Metastasis 12Breast Neoplasms, Male 12Ovarian Neoplasms 10Inflammatory Breast Neoplasms 7Glioblastoma 6Prostatic Neoplasms 5Endometrial Neoplasms 5Central Nervous System Neoplasms 5Gliosarcoma 4Fallopian Tube Neoplasms 4Breast Cancer Female 4Brain Neoplasms 4Glioma 3Carcinoma, Ovarian Epithelial 3Carcinoma, Ductal, Breast 3Breast Diseases 3Astrocytoma 3Uterine Cervical Neoplasms 2Urinary Bladder Neoplasms 2Sarcoma 2Recurrence 2Pancreatic Neoplasms 2Oligodendroglioma 2Medulloblastoma 2Liver Neoplasms 2Infertility 2

Interventions

niraparib 3Paclitaxel 2Letrozole 2trametinib 1ribociclib 1pembrolizumab 1liposomal doxorubicin 1Topotecan 1Taxes 1Tamoxifen 1Specimen Handling 1Nivolumab 1Magnetic Resonance Spectroscopy 1Ipilimumab 1Doxorubicin 1Diphenhydramine 1Dexamethasone 1Cimetidine 1CTLA-4 Antigen 1Blood Specimen Collection 1Axitinib 1AZD 6244 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Cystadenocarcinoma, Serous × Tamoxifen × Clear all
NCT02101788 2025-11-13

Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer

National Cancer Institute (NCI)

Phase 2/3 Completed
260 enrolled 20 charts

Cystadenocarcinoma, Serous

Data powered by HemOnc (CC BY 4.0) Colophon âš¡